Guardant is building the data-and-distribution flywheel for liquid biopsy—if Shield wins on real-world adherence and reimbursement holds, it can redefine population cancer detection.
Overview
Guardant Health is a leading precision oncology and molecular diagnostics company that helped shift cancer testing from invasive tissue biopsies to “blood-first” liquid biopsy. By early 2026 it has expanded from late-stage therapy selection into a vertically integrated platform spanning screening, early-stage recurrence monitoring, and advanced disease resistance tracking. Revenue is organized into Precision Oncology, Screening (Shield CRC blood test), and Biopharma/Data services leveraging a dataset of 1M+ samples. FY2025 revenue reached $982M (+33% YoY), driven by +34% oncology test volume growth and the initial Shield ramp. Shield’s key advantage is real-world adherence (93% in first 100k), supported by ADLT Medicare reimbursement of $1,495. Management targets company-wide free cash flow breakeven by Q4 2027, with the core oncology business already FCF positive in 2H 2025. Strategic moves—Quest distribution (March 2026) and the MetaSight acquisition—broaden reach and add new multiomic modalities, aiming to make Guardant the dominant data orchestrator in oncology.